Pharmaceuticals, Biotechnology & Life Sciences

Pfizer’s Litfulo phase‑III wins and new XFG‑variant COVID‑19 vaccine launch boost its dermatology and vaccinology portfolios with strong efficacy and safety.

Investors weigh Novo Nordisk’s €45 share price and GLP‑1 obesity strategy, noting slowing uptake of Wegovy and Zepbound, new combination therapies, and a 2030‑2033 patent cliff that could reshape market dynamics.

Explore how Johnson & Johnson’s ovarian‑cancer settlement and Rybrevant’s FDA priority review impact its stock, while new IBD therapy shows promise for future growth.

Explore how Shionogi & Co. Ltd’s long‑acting HIV therapies gain market share, leverage real‑world data, and navigate patent cliffs for future growth.

Kyowa Kirin secures EMA approval for Repatha, offering twice‑yearly PCSK9 therapy that cuts major cardiovascular events by 28 % in high‑risk patients.

First‑quarter 2026: Piramal Pharma shows steady revenue growth, higher EBITDA, and strong FDA compliance, positioning it for continued success in CDMO, generics, and consumer‑healthcare markets.

Syngene International reports a 17% revenue drop in Q1 FY 2027 but plans to rebound with AI‑driven Syn.AI, new partnerships and governance upgrades.

Explore how Pfizer‑BioNTech’s EU XFG‑variant COVID‑19 vaccine secures market access, drives €4.2 bn revenue, and navigates patent cliffs and supply‑chain risks.

How Novo Nordisk’s Wegovy growth, cell‑based platform, and legal challenges shape its future in obesity and diabetes markets.

Johnson & Johnson’s $1.2 billion Firefly Bio deal and Sail Biomedicines partnership boost oncology and CAR‑T portfolios, offering patent protection and high‑growth market access.